Avior Wealth Management’s Cullinan Oncology CGEM Stock Holding History

Avior Wealth Management’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5	Closed	-$85	–	2524
2024 Q1	$85	Buy	+5	New	+$77	﹤0.01%	3250

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avior Wealth Management's CGEM Position: Q2 2024 in Review

Avior Wealth Management sold out of Cullinan Oncology (CGEM) in Q2 2024, closing a stake of 5 shares — an estimated $85 sold.

Avior Wealth Management first reported a position in CGEM in Q1 2024 and held it in 1 quarter. The position peaked at $85 in Q1 2024. 135 funds tracked by Wall St. Rank hold CGEM as of Q2 2024.

Avior Wealth Management reported no remaining Cullinan Oncology position as of Q2 2024 after selling out during the quarter.
Avior Wealth Management sold 5 Cullinan Oncology shares in Q2 2024, an estimated $85.
Avior Wealth Management first reported a position in Cullinan Oncology in Q1 2024 and held it in 1 quarter.
Avior Wealth Management's Cullinan Oncology position peaked at $85 in Q1 2024.
135 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.